UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee
Unity Biotechnology, Inc. (UBX)
Last unity biotechnology, inc. earnings: 3/11 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically meaningful impact on pain Call with management scheduled for today at 8:00 a.m. EDT SAN FRANCISCO, June 18, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced promising results from its first-in-human Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee. The study demonstrated that UBX0101 was safe and well-tolerated. Improvement in several clinical measures, including
Read more
Impact Snapshot
Event Time:
UBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UBX alerts
High impacting Unity Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
UBX
News
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at Chardan Capital from $6.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.MarketBeat
- Unity Biotechnology, Inc. (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of DirectorsGlobeNewswire
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
UBX
Earnings
- 5/14/24 - Beat
UBX
Sec Filings
- 4/3/25 - Form 144
- 4/3/25 - Form 4
- 4/3/25 - Form 144
- UBX's page on the SEC website